> top > docs > PubMed:32264791 > annotations

PubMed:32264791 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T7984 750-758 SP_10 denotes SARS-CoV
T7974 0-31 PG_10 denotes Angiotensin Converting Enzyme 2
T7975 33-43 SP_7 denotes SARS-CoV-2
T7976 131-135 G_3;PG_10 denotes ACE2
T7977 328-336 SP_10 denotes SARS-CoV
T7978 341-351 SP_7 denotes SARS-CoV-2
T7979 362-366 G_3;PG_10 denotes ACE2
T7980 494-498 G_3;PG_10 denotes ACE2
T7981 535-545 SP_7 denotes SARS-CoV-2
T7982 592-600 SP_7 denotes COVID-19
T7983 660-664 G_3;PG_10 denotes ACE2
T7985 791-801 SP_7 denotes SARS-CoV-2
T7986 894-899 SP_6;PG_10 denotes human
T7987 900-904 PG_10 denotes ACE2
T7988 949-962 BV_19 denotes pathogenicity
T7989 966-976 SP_7 denotes SARS-CoV-2
T7990 990-994 G_3;PG_10 denotes ACE2
T7991 1025-1035 SP_7 denotes SARS-CoV-2
T7992 1120-1124 G_3;PG_10 denotes ACE2
T7993 1380-1384 G_3;PG_10 denotes ACE2
T7994 1504-1508 G_3;PG_10 denotes ACE2
T7995 1527-1531 G_3;PG_10 denotes Ace2
T7996 1558-1575 CHEBI:48561 denotes receptor agonists
T7997 1584-1588 G_3;PG_10 denotes ACE2
T7998 1698-1703 SP_6;PG_10 denotes human
T7999 1704-1708 PG_10 denotes ACE2
T8000 1783-1797 DG_37 denotes angiotensin II
T8001 1933-1937 G_3;PG_10 denotes ACE2
T8002 1951-1961 SP_7 denotes SARS-CoV-2
T8003 2048-2056 SP_7 denotes COVID-19

LitCovid_AGAC

Id Subject Object Predicate Lexical cue
p125237s33 868-875 Interaction denotes binding
p125237s34 876-884 Interaction denotes affinity
p125238s1 982-986 NegReg denotes loss
p125238s3 990-994 Protein denotes ACE2
p125238s18 1065-1075 PosReg denotes activation
p125242s10 1584-1595 MPA denotes ACE2 action

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-99 Sentence denotes Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System.
T2 100-361 Sentence denotes Angiotensin-converting enzyme (ACE2) has a multiplicity of physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system (RAS), facilitator of amino acid transport, and the SARS-CoV and SARS-CoV-2 receptor.
T3 362-493 Sentence denotes ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue.
T4 494-693 Sentence denotes ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for COVID-19, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease.
T5 694-977 Sentence denotes Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2.
T6 978-1115 Sentence denotes The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing.
T7 1116-1321 Sentence denotes The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes.
T8 1322-1491 Sentence denotes The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications.
T9 1492-1685 Sentence denotes Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS.
T10 1686-1839 Sentence denotes Recombinant human ACE2 has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively.
T11 1840-2105 Sentence denotes Our review summarizes the progress over the past 20 years, highlighting the critical role of ACE2 as the novel SARS-CoV-2 receptor and as the negative regulator of the RAS, together with implications for the COVID-19 pandemic and associated cardiovascular diseases.
T1 0-99 Sentence denotes Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System.
T2 100-361 Sentence denotes Angiotensin-converting enzyme (ACE2) has a multiplicity of physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system (RAS), facilitator of amino acid transport, and the SARS-CoV and SARS-CoV-2 receptor.
T3 362-493 Sentence denotes ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue.
T4 494-693 Sentence denotes ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for COVID-19, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease.
T5 694-977 Sentence denotes Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2.
T6 978-1115 Sentence denotes The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing.
T7 1116-1321 Sentence denotes The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes.
T8 1322-1491 Sentence denotes The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications.
T9 1492-1685 Sentence denotes Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS.
T10 1686-1839 Sentence denotes Recombinant human ACE2 has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively.
T11 1840-2105 Sentence denotes Our review summarizes the progress over the past 20 years, highlighting the critical role of ACE2 as the novel SARS-CoV-2 receptor and as the negative regulator of the RAS, together with implications for the COVID-19 pandemic and associated cardiovascular diseases.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 159-361 DRI_Background denotes physiological roles that revolve around its trivalent function: a negative regulator of the renin-angiotensin system (RAS), facilitator of amino acid transport, and the SARS-CoV and SARS-CoV-2 receptor.
T2 362-493 DRI_Background denotes ACE2 is widely expressed, including, in the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue.
T3 494-693 DRI_Background denotes ACE2 has recently been identified as the SARS-CoV-2 receptor, the infective agent responsible for COVID-19, providing a critical link between immunity, inflammation, ACE2, and cardiovascular disease.
T4 694-977 DRI_Background denotes Although sharing a close evolutionary relationship with SARS-CoV, the receptor-binding domain of SARS-CoV-2 differs in several key amino acid residues, allowing for stronger binding affinity with the human ACE2 receptor, which may account for the greater pathogenicity of SARS-CoV-2.
T5 978-1115 DRI_Background denotes The loss of ACE2 function following binding by SARS-CoV-2 is driven by endocytosis and activation of proteolytic cleavage and processing.
T6 1116-1321 DRI_Challenge denotes The ACE2 system is a critical protective pathway against heart failure with reduced and preserved ejection fraction including, myocardial infarction and hypertension, and against lung disease and diabetes.
T7 1322-1491 DRI_Background denotes The control of gut dysbiosis and vascular permeability by ACE2 has emerged as an essential mechanism of pulmonary hypertension and diabetic cardiovascular complications.
T8 1492-1685 DRI_Outcome denotes Recombinant ACE2, gene-delivery of Ace2, Ang 1-7 analogs, and Mas receptor agonists enhance ACE2 action and serve as potential therapies for disease conditions associated with an activated RAS.
T9 1686-1839 DRI_Background denotes Recombinant human ACE2 has completed clinical trials and efficiently lowered or increased plasma angiotensin II and angiotensin 1-7 levels, respectively.